<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03706911</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-VM1500ALAI-01</org_study_id>
    <nct_id>NCT03706911</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI Single and Multiple Ascending Doses in Healthy Subjects</brief_title>
  <official_title>Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI Single and Multiple Ascending Doses in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viriom</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viriom</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate safety, tolerability and pharmacokinetics of VM-1500A-LAI single&#xD;
      and multiple ascending doses in healthy subjects. The study will be conducted in 1&#xD;
      investigational site in Russia in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study to evaluate safety, tolerability and pharmacokinetics of a long-acting&#xD;
      injectable NNRTI VM-1500A-LAI single and multiple ascending doses in healthy subjects. The&#xD;
      study will be conducted in 1 investigational site in Russia in healthy volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">December 2018</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of AEs and SAEs</measure>
    <time_frame>4 weeks for SAD, 8 weeks for MAD</time_frame>
    <description>The incidence of adverse events (AEs) and serious adverse events (SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>concentration of VM1500A in plasma</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of VM1500A in BFE</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of VM1500A in PBMC</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>VM-1500A-LAI 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500A-LAI 50mg IM single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VM-1500A-LAI 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500A-LAI 150mg IM single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VM-1500A-LAI 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500A-LAI 300mg IM single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VM-1500A-LAI 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500A-LAI 600mg IM single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VM-1500A-LAI 1200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500A-LAI 1200mg IM single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VM-1500A-LAI XXX5mg Multiple</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500A-LAI selected dose IM, 2 injections monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VM-1500A-LAI XXX6mg Multiple</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500A-LAI double selected dose IM, 2 injections monthly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VM-1500A-LAI</intervention_name>
    <description>VM1500A (parent drug of elsulfavirine) IM injection dosage form</description>
    <arm_group_label>VM-1500A-LAI 1200mg</arm_group_label>
    <arm_group_label>VM-1500A-LAI 150mg</arm_group_label>
    <arm_group_label>VM-1500A-LAI 300mg</arm_group_label>
    <arm_group_label>VM-1500A-LAI 50mg</arm_group_label>
    <arm_group_label>VM-1500A-LAI 600mg</arm_group_label>
    <arm_group_label>VM-1500A-LAI XXX5mg Multiple</arm_group_label>
    <arm_group_label>VM-1500A-LAI XXX6mg Multiple</arm_group_label>
    <other_name>VM1500A-LAI</other_name>
    <other_name>VM1500A</other_name>
    <other_name>VM-1500A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Non-smoking healthy male subjects between the ages of 18 and 45 years (inclusive);&#xD;
&#xD;
          2. Verified diagnosis of &quot;healthy&quot; according to standard clinical, laboratory and&#xD;
             instrumental examination methods;&#xD;
&#xD;
          3. Body weight ≥ 50 kg and Body Mass Index from 18.5 to 30.0 kg/m2;&#xD;
&#xD;
          4. Signed the Participant Explanation Sheet and the Informed Consent Form; Consent to use&#xD;
             an adequate double method of contraception throughout the study and 3 months after its&#xD;
             completion in the form of a condom with spermicide (in the form of cream, jelly, foam)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chronic diseases of cardiovascular, bronchopulmonary, neuroendocrine, musculoskeletal&#xD;
             system and gastrointestinal tract, as well as immunologic, liver, kidneys, blood&#xD;
             diseases;&#xD;
&#xD;
          2. Deviations of laboratory parameters from normal values at screening (the acceptable&#xD;
             limits of laboratory parameters are specified in Annex 1), as well as deviations from&#xD;
             the normal values on the ECG results;&#xD;
&#xD;
          3. Systolic pressure less than 90 mm Mercury or above 130 mm Mercury, diastolic pressure&#xD;
             less than 60 mm Mercury or above 85 mm Mercury, heart rate less than 60 BPM or more&#xD;
             than 90 BPM at screening;&#xD;
&#xD;
          4. Regular intake of drugs less than 2 weeks prior to screening (including herbal&#xD;
             preparations and dietary supplements); intake of drugs that have a pronounced effect&#xD;
             on hemodynamics, liver, kidney and CNS function and etc. (for example, barbiturates,&#xD;
             omeprazole, cimetidine, etc.) less than 4 weeks prior to screening;&#xD;
&#xD;
          5. Presence of antibodies to HIV and hepatitis C virus, presence of hepatitis В surface&#xD;
             antigen, a positive syphilis test;&#xD;
&#xD;
          6. Presence of an unstable sleep structure (for example, night work, sleep disturbances,&#xD;
             insomnia, recent return from another time zone, etc.);&#xD;
&#xD;
          7. Signs of alcohol (taking more than 10 units of alcohol per week ) or drug addiction;&#xD;
             alcohol or drugs consumption within 7 days prior to screening; cigarettes smoking 3&#xD;
             months prior to screening; positive drug and alcohol test at screening;&#xD;
&#xD;
          8. Presence of depression episodes or other mental disorders/conditions that require&#xD;
             medical therapy in history;&#xD;
&#xD;
          9. Burdened allergic medical history (including drug intolerance and food allergy);&#xD;
&#xD;
         10. Blood/plasma donation (450 ml of blood or plasma and more) less than 12 months prior&#xD;
             to screening, surgery;&#xD;
&#xD;
         11. Presence of diseases and conditions in the present or past, including surgery, which,&#xD;
             according to the Investigator, may affect the absorption, distribution, metabolism or&#xD;
             excretion of the study drug;&#xD;
&#xD;
         12. Participation in other clinical studies or taking other study drugs 3 months before&#xD;
             screening;&#xD;
&#xD;
         13. Acute infectious diseases less than 4 weeks prior to screening;&#xD;
&#xD;
         14. Incapable of reading or writing; no desire to understand and adhere to the study&#xD;
             protocol procedures; non-compliance with the drugs intake regimen or execution of&#xD;
             procedures, which as the Investigator may think may affect the study results or&#xD;
             subject's safety and prevent the subject from further participation in the study; any&#xD;
             other associated medical or serious psychological conditions making the subject not&#xD;
             eligible to participate in the clinical study, restricting legality of obtaining the&#xD;
             informed consent or affecting the subject's ability to take part in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Smolyarchuk, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>I.M. Sechenov First Moscow State Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena Yakubova, PhD</last_name>
    <phone>+7 (495) 995-49-44</phone>
    <email>ey@chemrar.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vladimir Kan, PhD</last_name>
    <phone>7 (495) 995-49-44</phone>
    <email>vkan@chemrar.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>I.M. Sechenov First Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119146</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <last_name>Elena Smolyarchuk, PhD</last_name>
      <phone>+7 499 248 6479</phone>
    </contact>
    <investigator>
      <last_name>Elena Smolyarchuk, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2018</study_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

